Stock AnalizBiogen (BIIB) earnings for the quarter ended September 2026: EPS beats estimates
Biogen reported results for the quarter ended September 2026 on October 28, 2026. Adjusted earnings per share came in at $2.62 against the analysts’ average forecast of $1.99, a beat of 31.5%.
Revenue for the quarter was $2.80 billion, up 10.6% from $2.53 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 3.4% on the first trading day after the report.
The last four quarters
Biogen has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $2.62 | $1.99 | +31.5% | +11% | −3.4% |
| Jun 2026 | $3.60 | $2.03 | +77.4% | — | +1.1% |
| Mar 2026 | $3.57 | $2.95 | +20.9% | +2% | +3.2% |
| Dec 2025 | $1.99 | $1.62 | +23.2% | −7% | +4.6% |
What comes next
Analysts expect EPS of $2.82 for the next quarter on average and $12.53 for the fiscal year ending December 31, 2026.
The average analyst price target is $268.26, 6% above the current price of $253.40.
Valuation and score
Biogen scores 1.8 out of 5 overall on Stock Analiz (weak), trades at a trailing P/E of about 109.2, and its intrinsic value under moderate assumptions is about 33% below the current market value. Full Biogen analysis with 10 years of financials
Frequently asked questions
What was Biogen’s EPS for the quarter ended September 2026?
$2.62 adjusted per share, against an analyst consensus of $1.99.
How much revenue did Biogen report?
$2.80 billion, up 10.6% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.